Pharmaceuticals
Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with symptomatic heart failure who have iron deficiency ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL...
2023-06-05 21:00
2882
Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing
News Summary: * Integration of Sartorius' process scale multi-column chromatography with Waters' process analytical technology to provide robust analytical data for downstream biomanufacturing of mAbs, recombinant proteins, vaccines, and other biologics. * Integrated solution to deliver vita...
2023-06-05 20:00
2604
Prenetics Announces First Quarter 2023 Financial Results
HONG KONG, June 5, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the first quarter endedMarch 31, 2023, along with recent business updates. First Quarter 2023 Fi...
2023-06-05 19:20
3212
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the in...
2023-06-05 19:12
2714
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-05 08:00
4615
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-06-03 07:59
22044
Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.
SUZHOU, China, June 2, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2023 ASCO Business Update Call conference onJune 7, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, research...
2023-06-02 19:14
4942
Latest Updates of 9 Viva's Portfolio Companies
HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2023-06-02 18:51
3190
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-02 08:00
5662
EVERSANA Forms Strategic Alliance with China Resource Pharmaceutical Commercial Group to Bring New Novel Treatments to Patients Globally
BEIJING, June 2, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution ent...
2023-06-02 00:10
2807
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
2023-06-02 00:06
6702
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2023-06-01 20:30
2635
Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
VIENNA, June 1, 2023 /PRNewswire/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets includin...
2023-06-01 17:18
3155
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion b...
2023-06-01 10:09
2966
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
BRII-297, a first-of-its-kind treatment option for anxiety and depressive
disorders, has the potential to enable greater therapeutic adherence and
convenience for patients
DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences
Limited
2023-06-01 08:00
2469
Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting
JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immun...
2023-06-01 00:55
2303
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected to be completed in Q2 2024, and the topline results are anticipated in Q3 2024. TAIPEI, May 31, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals, a biopharmaceutical company focusing on breakthroug...
2023-05-31 20:15
2886
SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
* SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract * SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients ...
2023-05-31 14:58
1726
Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement
EAST RUTHERFORD, N.J, May 31, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific...
2023-05-31 14:30
1946
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients
SHANGHAI, May 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiat...
2023-05-31 11:39
2011
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
10036
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7286
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
6451
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
6062
